Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Serono and Nautilus to develop next generation of human growth hormone

Nov. 16, 2004

Bridge financing to fund initiation of Oxycyte phase II trial

Nov. 16, 2004

Azetidinone derivatives described in patent literature

Nov. 15, 2004

Sankyo scientists test a series of oligosaccharides

Nov. 15, 2004

Sumitomo's SMP-797 shows promise as a novel hypolipidemic drug

Nov. 15, 2004

Wyeth selects novel drug targets in osteoporosis collaboration with Galapagos

Nov. 15, 2004

DeveloGen receives R&D funding for diabetic complications efforts

Nov. 15, 2004

MannKind plans phase III for Technosphere Insulin System

Nov. 15, 2004

Merck selects integrin alphavbeta3 antagonist for development for osteoporosis

Nov. 12, 2004

LR-103 effective in bone parameter normalization in secondary hyperparathyroidism transgenic model

Nov. 11, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...